Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Massachusetts 02114, USA.
Nature. 2011 Nov 13;480(7375):99-103. doi: 10.1038/nature10630.
So far, two genes associated with familial melanoma have been identified, accounting for a minority of genetic risk in families. Mutations in CDKN2A account for approximately 40% of familial cases, and predisposing mutations in CDK4 have been reported in a very small number of melanoma kindreds. Here we report the whole-genome sequencing of probands from several melanoma families, which we performed in order to identify other genes associated with familial melanoma. We identify one individual carrying a novel germline variant (coding DNA sequence c.G1075A; protein sequence p.E318K; rs149617956) in the melanoma-lineage-specific oncogene microphthalmia-associated transcription factor (MITF). Although the variant co-segregated with melanoma in some but not all cases in the family, linkage analysis of 31 families subsequently identified to carry the variant generated a log of odds (lod) score of 2.7 under a dominant model, indicating E318K as a possible intermediate risk variant. Consistent with this, the E318K variant was significantly associated with melanoma in a large Australian case-control sample. Likewise, it was similarly associated in an independent case-control sample from the United Kingdom. In the Australian sample, the variant allele was significantly over-represented in cases with a family history of melanoma, multiple primary melanomas, or both. The variant allele was also associated with increased naevus count and non-blue eye colour. Functional analysis of E318K showed that MITF encoded by the variant allele had impaired sumoylation and differentially regulated several MITF targets. These data indicate that MITF is a melanoma-predisposition gene and highlight the utility of whole-genome sequencing to identify novel rare variants associated with disease susceptibility.
迄今为止,已经确定了两个与家族性黑色素瘤相关的基因,这些基因占家族遗传风险的一小部分。CDKN2A 基因突变约占家族性病例的 40%,而 CDK4 易感性突变则在极少数黑色素瘤家族中报道过。在这里,我们报告了来自几个黑色素瘤家族的先证者的全基因组测序结果,我们进行这些测序是为了鉴定与家族性黑色素瘤相关的其他基因。我们在一个黑色素瘤谱系特异性癌基因小眼畸形相关转录因子(MITF)中发现了一个个体携带一种新的种系变异(编码 DNA 序列 c.G1075A;蛋白序列 p.E318K;rs149617956)。尽管该变体在家族中的一些但不是所有病例中与黑色素瘤共分离,但随后对携带该变体的 31 个家族进行连锁分析,在显性模型下产生了 2.7 的对数优势(lod)评分,表明 E318K 是一种可能的中间风险变体。与此一致的是,E318K 变体在一个大型澳大利亚病例对照样本中与黑色素瘤显著相关。同样,在英国的一个独立病例对照样本中也存在类似的相关性。在澳大利亚样本中,携带该变体等位基因的个体在有黑色素瘤家族史、多个原发性黑色素瘤或两者兼有的病例中明显占优势。该变体等位基因也与痣数量增加和非蓝色眼睛颜色相关。E318K 的功能分析表明,该变体编码的 MITF 具有受损的 SUMOylation 并差异调节几个 MITF 靶标。这些数据表明 MITF 是一种黑色素瘤易感性基因,并强调了全基因组测序识别与疾病易感性相关的新型罕见变体的效用。